logo-loader
AIM:AVCT

Avacta Group PLC

Receive alerts
Market:
AIM
Price
60.50 GBX
Day Change
6.51%
Market Cap:
£264.77 m
52 weeks high
92.00
52 weeks low
48.00

In brief

At Avacta we have developed Affimer technology, an engineered alternative to antibodies. Based on a small protein, Affimer technology can be quickly developed to bind with high specificity and affinity to a wide range of targets.

Affimer proteins can be developed as therapeutic molecules and can be used in a wide range of other life sciences applications in research and diagnostics.